Capricor Gets Three Extra Months as FDA Reviews Stronger Upper-Limb Data for Deramiocel

FDA extends Capricor’s Deramiocel BLA review to Nov 22, 2026 after new 24-month HOPE-3 data focused on upper limb function in Duchenne MD.